Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
Hodder SL, Mounzer K, Dejesus E, Ebrahimi R, Grimm K, Esker S, Ecker J, Farajallah A, Flaherty JF; AI266073 Study Group. Hodder SL, et al. Among authors: esker s. AIDS Patient Care STDS. 2010 Feb;24(2):87-96. doi: 10.1089/apc.2009.0259. AIDS Patient Care STDS. 2010. PMID: 20156091 Clinical Trial.
HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXd.
Singer CF, Jahn SW, Hlauschek D, Heber UM, Mang-Manger C, Egle D, Balic M, Pichler A, Pfeiler G, Kacerovsky-Strobl S, Suppan C, Ritter M, Petru E, Greil R, Bago-Horvath Z, Deutschmann C, Steger GG, Seifert M, Fitzal F, Bartsch R, Santhanagopal A, Machacek-Link J, Sellami D, Schwarz M, Fesl C, Sölkner L, Esker S, Filipits M, Gnant M; Austrian Breast and Colorectal Cancer Study Group. Singer CF, et al. Among authors: esker s. Cancer Commun (Lond). 2025 Jan 6. doi: 10.1002/cac2.12657. Online ahead of print. Cancer Commun (Lond). 2025. PMID: 39757921 No abstract available.
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response.
Brasó-Maristany F, Ferrero-Cafiero JM, Falato C, Martínez-Sáez O, Cejalvo JM, Margelí M, Tolosa P, Salvador-Bofill FJ, Cruz J, González-Farré B, Sanfeliu E, Òdena A, Serra V, Pardo F, Luna Barrera AM, Arumi M, Guerra JA, Villacampa G, Sánchez-Bayona R, Ciruelos E, Espinosa-Bravo M, Izarzugaza Y, Galván P, Matito J, Pernas S, Vidal M, Santhanagopal A, Sellami D, Esker S, Fan PD, Suto F, Vivancos A, Pascual T, Prat A, Oliveira M. Brasó-Maristany F, et al. Among authors: esker s. Nat Commun. 2024 Jul 11;15(1):5826. doi: 10.1038/s41467-024-50056-y. Nat Commun. 2024. PMID: 38992028 Free PMC article.
Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic or Unresectable EGFR-Mutated Non-Small Cell Lung Cancer Previously Treated with Osimertinib and Platinum-Based Chemotherapy.
Patel J, Meng J, Le H, Tanaka Y, Phani S, Salas M, Wu C, Sternberg D, Esker S, Anderson JP, Crowley A, Zhou SQ, Lieb C, Sun H, Doan QV, Santhanagopal A, Reckamp KL. Patel J, et al. Among authors: esker s. Adv Ther. 2024 Aug;41(8):3299-3315. doi: 10.1007/s12325-024-02936-4. Epub 2024 Jul 3. Adv Ther. 2024. PMID: 38958845 Free PMC article.
15 results